Novartis Drug Failure Shakes Billion-Dollar Cholesterol Race
A Novartis setback in lowering Lp(a) levels puts pressure on Amgen and Eli Lilly to prove the approach can prevent heart attacks.
A high-stakes pharmaceutical race to develop next-generation cholesterol-lowering drugs suffered a significant blow after Novartis reported a failure in its effort to reduce a dangerous lipid known as Lp(a), casting fresh uncertainty over whether cutting those levels actually translates into fewer heart attacks and strokes for patients.
The setback matters beyond Novartis alone. Rival drugmakers Amgen and Eli Lilly are deep in their own multibillion-dollar programs targeting the same biological pathway, and the Novartis stumble now raises hard questions about whether the entire therapeutic class can deliver on its promise — or whether lower Lp(a) readings are simply a lab marker that doesn't move the needle on real-world cardiovascular outcomes.
Read more AstraZeneca COPD Drug Wins Two Late-Stage Trials, Eyes $5B Peak Sales →
Lp(a), a genetically determined lipoprotein long associated with elevated cardiovascular risk, has attracted intense industry interest precisely because existing statin therapies do little to reduce it. The logic was compelling: if you could bring Lp(a) down, you could potentially unlock a new frontier in heart disease prevention for millions of patients who remain at risk even while on standard cholesterol medications.
But pharmaceutical history is littered with drugs that moved biomarkers without moving mortality or event rates, and Novartis' result revives that uncomfortable pattern. Investors and cardiologists alike will now watch Amgen and Eli Lilly's late-stage trial readouts with far greater scrutiny, as the two companies carry the weight of validating — or invalidating — the broader scientific thesis.
The competitive and commercial consequences are enormous. Heart disease remains the leading cause of death in the United States, and a proven Lp(a)-lowering therapy would command a vast and largely untreated patient market. Whether that opportunity still exists now depends heavily on what Amgen and Lilly's data ultimately show. Continue reading at US Top News and Analysis.
